ALLERGAN
LIVE

Serial Number

87742107

Owner

Allergan Sales, LLC

Attorney

Matthew O. Brady

First Use Date

Jun 30, 2017

Filing Date

Jan 3, 2018

Add to watchlist:

No watchlists yet
View on USPTO

ALLERGAN Trademark

Serial Number: 87742107 • Registration: 6420206

ALLERGAN is a trademark filed by Allergan Sales, LLC on January 3, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Allergan Sales, LLC (6 trademarks)

1 N. Waukegan Road
North Chicago, IL 60064

Entity Type: 16

Trademark Details

Filing Date

January 3, 2018

Registration Date

July 13, 2021

First Use Anywhere

June 30, 2017

First Use in Commerce

June 30, 2017

Published for Opposition

April 17, 2018

Goods & Services

House mark used for a line of pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations, and pharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body; medicated cosmetic skin care preparations

House mark used for a line of surgical, medical, dental and veterinary apparatus and instruments, namely, diagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for use in facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics and ophthalmic related diseases and disorders

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 13, 2026 REM1
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jul 6, 2026 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 6, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 6, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 6, 2026 REAP
REGISTERED-PRINCIPAL REGISTER
Jul 13, 2021 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jun 9, 2021 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jun 8, 2021 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Jun 7, 2021 SUPC
USE AMENDMENT FILED
Jun 4, 2021 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 4, 2021 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 30, 2020 EXRA
SOU EXTENSION 5 GRANTED
Dec 29, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 29, 2020 AITU
SOU EXTENSION 5 FILED
Dec 10, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Dec 10, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 16, 2020 EXRA
SOU EXTENSION 4 GRANTED
Jun 12, 2020 EX4G
SOU EXTENSION 4 FILED
Jun 12, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 12, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 10, 2019 EXRA
SOU EXTENSION 3 GRANTED
Dec 6, 2019 EX3G
SOU EXTENSION 3 FILED
Dec 6, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Dec 6, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 14, 2019 EXRA
SOU EXTENSION 2 GRANTED
Jun 12, 2019 EX2G
SOU EXTENSION 2 FILED
Jun 12, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 12, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 1, 2018 EXRA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 29, 2018 TCCA
SOU EXTENSION 1 GRANTED
Nov 29, 2018 EX1G
SOU EXTENSION 1 FILED
Nov 29, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 29, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 12, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 17, 2018 NPUB
PUBLISHED FOR OPPOSITION
Apr 17, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 28, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 14, 2018 CNSA
ASSIGNED TO EXAMINER
Mar 13, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 18, 2018 NWOS
NEW APPLICATION ENTERED
Jan 6, 2018 NWAP